SCHEMBL6944186

SCHEMBL6944186

Cc1nc(Oc2ccc3c(c2)OCO3)nc(Cl)c1C

nearest known ligand 0.50

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.50
KMT2A Q03164 1/20 0.50
ALDH1A1 P00352 2/20 0.46
MAPK1 P28482 2/20 0.46
NOS2 P35228 7/20 0.45
MAOB P27338 3/20 0.43
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
LMNA P02545 1/20 0.41
TP53 P04637 1/20 0.41
TSHR P16473 1/20 0.40
MAPT P10636 1/20 0.39
GAA P10253 1/20 0.39
MAOA P21397 1/20 0.39
ALOX5 P09917 1/20 0.38
PIK3CD O00329 1/20 0.38
HIF1A Q16665 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6939958 0.93 MEN1 (0.53) MEN1KMT2AALDH1A1MAPK1NOS2
SCHEMBL6942370 0.81 NOS2 (0.56) MEN1KMT2AALDH1A1MAPK1NOS2
SCHEMBL22162810 0.81 MEN1 (0.64) MEN1KMT2AALDH1A1MAPK1NOS2
SCHEMBL6944845 0.80 NOS2 (0.54) MEN1KMT2AALDH1A1MAPK1NOS2
SCHEMBL6945142 0.78 NPC1 (0.47) MEN1KMT2AALDH1A1MAPK1NOS2
SCHEMBL6941212 0.74 NOS2 (0.72) MEN1KMT2AMAPK1NOS2MAOB
SCHEMBL6937888 0.74 NOS2 (0.72) MEN1KMT2AMAPK1NOS2MAOB
SCHEMBL6942398 0.73 NOS2 (0.51) MEN1KMT2AALDH1A1MAPK1NOS2
SCHEMBL6947003 0.72 NOS2 (0.54) MEN1KMT2AALDH1A1MAPK1NOS2
SCHEMBL6165864 0.72 ALDH1A1 (0.78) MEN1KMT2AALDH1A1MAPK1MAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1268471-B1 N-HETEROCYCLIC DERIVATIVES AS NOS INHIBITORS SCHERING AG (DE) 2003-10-15 EP disclosed
US-6525051-B2 N-heterocyclic derivatives as NOS inhibitors SCHERING AKTIENGESELLSCHAFT (DE) 2003-02-25 US disclosed
EP-1268471-A1 N-HETEROCYCLIC DERIVATIVES AS NOS INHIBITORS SCHERING AKTIENGESELLSCHAFT (DE) 2003-01-02 EP disclosed
US-20020010190-A1 N-heterocyclic derivatives as NOS inhibitors SCHERING AKTIENGESELLSCHAFT (DE) 2002-01-24 US disclosed
WO-2001072744-A1 N-HETEROCYCLIC DERIVATIVES AS NOS INHIBITORS SCHERING AKTIENGESELLSCHAFT (DE) 2001-10-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020010190-A1 N-heterocyclic derivatives as NOS inhibitors NOS1, NOS3, NOS2 MEN1 3177/4885KMT2A 2660/4885ALDH1A1 573/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.